Home/Pipeline/Oncology Discovery

Oncology Discovery

Oncology

Research/Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Research/Pre-clinical

Status

Active

Company

Adamed

About Adamed

Adamed Pharma S.A. is a mature, family-owned Polish biopharmaceutical company with nearly 40 years of operational history. It has evolved from a domestic player into an international organization with a diversified commercial portfolio spanning 19 therapeutic areas and a growing proprietary R&D pipeline focused on oncology, CNS disorders, and mRNA vaccines. The company is in a strong commercial phase, evidenced by recent strategic moves like the acquisition of a manufacturing facility in Spain and the launch of a new advanced R&D center, Adamed Discovery, positioning it for further growth in innovative therapeutics.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS) Disorders Multiple Chronic Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active